Douglas Melton, Co-Director of the Harvard Stem Cell Institute (HSCI), has received a financial grant from His Highness Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi. The grant will bolster HSCI research focusing on accelerating gene editing approaches for pancreatic beta cell replacement therapy.
According to the World Health Organization, about 422 million people worldwide have diabetes, and 1.6 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few...
Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). In conjunction with immunosuppressive therapy, VX-880 produced robust restoration of islet cell function on Day 90 in the first patient in its Phase 1/2 clinical trial.... Read more about A new therapy for treating Type 1 diabetes
The JDRF Center of Excellence in New England will accelerate beta cell replacement therapy
Harvard Stem Cell Institute (HSCI) co-director Douglas Melton, Ph.D., will lead a new multi-institutional center funded by JDRF to advance type 1 diabetes research. The JDRF Center of Excellence in New England will focus on the transplantation of beta cells, the insulin-producing cells of the pancreas that are attacked by the immune system during type 1 diabetes.
The center is also led by JDRF scientific staff leader Esther Latres, Ph.D. Other collaborators include...
The Harvard Stem Cell Institute (HSCI) was launched in 2004 with the express goal of pursuing the promise of stem cell science. In April 2019 we celebrate our 15th anniversary, and reflect on how far we have come.
Collaboration across Harvard
Our founding document listed 28 participating Harvard faculty, including co-founders Doug Melton and David Scadden. By May 2004 that list had expanded to 39 faculty, and in 2005 the number had almost doubled.